DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/b29h7z/parkinsons_diseas) has announced the addition of GlobalData's new report "Parkinson's Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020" to their offering.
GlobalData has released its pharma report, Parkinson's Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020. The report is an essential source of information and analysis on the global Parkinson's disease Therapeutics therapeutics market. The report provides comprehensive information on Parkinson's Disease Therapeutics, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global Parkinson's Disease Therapeutics therapeutics market. It analyses the treatment usage patterns in the global Parkinson's Disease Therapeutics therapeutics market.
The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global Parkinson's Disease Therapeutics sector. It quantifies the unmet need in the global Parkinson's Disease Therapeutics therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players. This report is built using data and information sourced from proprietary databases, primary and secondary research.
Parkinson's Disease (PD) Therapeutics Market is Forecast to Show Slow Growth to 2020
In 2011, the global Parkinson's Disease (PD) therapeutics market, which includes the key markets of the US, Japan, Germany, the UK, France, Italy, Spain, Brazil, China, India and Russia was estimated to be worth $2,992m. During the period 2002-2011, the global PD therapeutics market grew at a Compound Annual Growth Rate (CAGR) of 5.8%. GlobalData analysis shows that the market size was primarily driven by two key parameters: the increase in PD prevalence due to the increase in the aging population in the 11 key markets and the increasing cost of therapy.
Companies Mentioned
- Abbott Laboratories
- ACADIA Pharmaceuticals Inc
- Merck & Co.
- IMPAX Laboratories
- Newron Pharmaceuticals S.p.A
For more information visit http://www.researchandmarkets.com/research/b29h7z/parkinsons_diseas
Source: GlobalData